[go: up one dir, main page]

NO20031510L - Preparater og fremgangsmåter for reduksjon av plasmalipoprotein (a) og risikofaktorer ved kardiovaskul¶re sykdommer - Google Patents

Preparater og fremgangsmåter for reduksjon av plasmalipoprotein (a) og risikofaktorer ved kardiovaskul¶re sykdommer

Info

Publication number
NO20031510L
NO20031510L NO20031510A NO20031510A NO20031510L NO 20031510 L NO20031510 L NO 20031510L NO 20031510 A NO20031510 A NO 20031510A NO 20031510 A NO20031510 A NO 20031510A NO 20031510 L NO20031510 L NO 20031510L
Authority
NO
Norway
Prior art keywords
preparations
reduction
methods
risk factors
cardiovascular diseases
Prior art date
Application number
NO20031510A
Other languages
English (en)
Other versions
NO20031510D0 (no
Inventor
Matthias Rath
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of NO20031510D0 publication Critical patent/NO20031510D0/no
Publication of NO20031510L publication Critical patent/NO20031510L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20031510A 2000-10-03 2003-04-03 Preparater og fremgangsmåter for reduksjon av plasmalipoprotein (a) og risikofaktorer ved kardiovaskul¶re sykdommer NO20031510L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (2)

Publication Number Publication Date
NO20031510D0 NO20031510D0 (no) 2003-04-03
NO20031510L true NO20031510L (no) 2003-06-02

Family

ID=22892673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031510A NO20031510L (no) 2000-10-03 2003-04-03 Preparater og fremgangsmåter for reduksjon av plasmalipoprotein (a) og risikofaktorer ved kardiovaskul¶re sykdommer

Country Status (24)

Country Link
US (2) US6693129B2 (no)
EP (1) EP1324753A2 (no)
JP (1) JP2004525080A (no)
KR (1) KR20030070003A (no)
CN (1) CN100421659C (no)
AU (2) AU1145202A (no)
BR (1) BR0114526A (no)
CA (1) CA2424880A1 (no)
CZ (1) CZ20031167A3 (no)
EE (1) EE200300136A (no)
HR (1) HRP20030348A2 (no)
HU (1) HUP0303040A3 (no)
IL (2) IL155238A0 (no)
MX (1) MXPA03002964A (no)
NO (1) NO20031510L (no)
NZ (2) NZ545806A (no)
PL (1) PL212479B1 (no)
RO (1) RO120567B1 (no)
RU (1) RU2289406C2 (no)
SK (1) SK5252003A3 (no)
TR (1) TR200300594T2 (no)
UA (1) UA77660C2 (no)
WO (1) WO2002028379A2 (no)
ZA (1) ZA200302772B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100369605C (zh) * 2000-12-14 2008-02-20 三共株式会社 血液脂质改善剂组合物
JP2004521127A (ja) * 2001-02-27 2004-07-15 ニュートリション ２１、インコーポレイテッド 異常脂血症及び食事誘発性食後高血糖症のクロム／ビオチン療法
US20030054978A1 (en) * 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
AU2003262804A1 (en) 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
AU2003284962B2 (en) * 2002-10-24 2009-04-02 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
AU2004279298B2 (en) * 2003-09-29 2009-01-29 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
AU2005262228A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
WO2008103926A1 (en) * 2007-02-22 2008-08-28 Innlabs, Llc Vitamin c preparation
EP2134351B1 (en) 2007-03-13 2016-04-27 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
CA2639895C (en) * 2007-10-05 2014-06-10 David Rowland Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
RU2385722C1 (ru) * 2008-07-02 2010-04-10 Тимофей Георгиевич Кожока Фармацевтическая нейропротекторная, антиоксидантная, антигипоксантная, антиапоптотическая и мембранопротекторная композиция и способ лечения
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
EP3160459A1 (en) * 2014-06-24 2017-05-03 Dedraf Holding B.V. New mineral composition
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
KR20210110572A (ko) 2018-11-02 2021-09-08 뉴트리션 21, 엘엘씨 비디오 게이머의 인지 기능 개선을 위한 이노시톨 안정화 아르기닌 실리케이트 복합체 및 이노시톨을 함유하는 조성물
AU2019416047B2 (en) * 2018-12-26 2023-01-05 Colgate-Palmolive Company Specific co-aggregation inhibition by arginine
AU2020407071A1 (en) 2019-12-16 2022-07-07 Nutrition 21, Llc Methods of production of arginine-silicate complexes
WO2024003377A1 (en) 2022-07-01 2024-01-04 N.V. Nutricia Nutritional composition for stroke
IT202300020718A1 (it) * 2023-10-06 2025-04-06 Promin Prod Di Medicina Integrata S R L Composizione a base di inositolo e proantocianidine oligomeriche

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) * 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
KR19980703596A (ko) * 1990-10-01 1998-12-05 쉘비 캘버트 모스 주요 혈관 이상 상태를 억제하기 위한 베타-카로틴 및 비타민 e 치료법
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
PT1163904E (pt) * 2000-06-16 2006-07-31 Rath Matthias Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
DK1195159T3 (da) * 2000-10-09 2006-10-02 Matthias Dr Med Rath Terapeutisk kombination af ascorbat med lysin og arginin til forebyggelse eller behandling af cancer
US6974833B2 (en) * 2001-01-16 2005-12-13 Matthias Rath Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
WO2002064129A2 (en) * 2001-02-14 2002-08-22 Rath, Matthias Compositions of biochemical compounds involved in bioenergy metabolism of cells
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
WO2002028379A3 (en) 2003-02-27
KR20030070003A (ko) 2003-08-27
RU2289406C2 (ru) 2006-12-20
US20020094996A1 (en) 2002-07-18
HUP0303040A3 (en) 2005-05-30
NO20031510D0 (no) 2003-04-03
US20040157895A1 (en) 2004-08-12
PL365986A1 (en) 2005-01-24
PL212479B1 (pl) 2012-10-31
TR200300594T2 (tr) 2004-10-21
HUP0303040A2 (hu) 2003-12-29
SK5252003A3 (en) 2004-01-08
UA77660C2 (en) 2007-01-15
NZ545806A (en) 2008-04-30
CN100421659C (zh) 2008-10-01
IL155238A0 (en) 2003-11-23
US7244749B2 (en) 2007-07-17
IL185384A (en) 2008-06-05
AU2002211452B2 (en) 2005-10-27
ZA200302772B (en) 2004-10-18
RO120567B1 (ro) 2006-04-28
US6693129B2 (en) 2004-02-17
CN1477959A (zh) 2004-02-25
CZ20031167A3 (cs) 2003-12-17
EE200300136A (et) 2003-08-15
HRP20030348A2 (en) 2005-06-30
BR0114526A (pt) 2005-04-26
MXPA03002964A (es) 2004-12-06
WO2002028379A2 (en) 2002-04-11
NZ525390A (en) 2006-04-28
CA2424880A1 (en) 2002-04-11
JP2004525080A (ja) 2004-08-19
EP1324753A2 (en) 2003-07-09
AU1145202A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
NO20031510L (no) Preparater og fremgangsmåter for reduksjon av plasmalipoprotein (a) og risikofaktorer ved kardiovaskul¶re sykdommer
AU2003230751A8 (en) System and process for performing purchase transaction using tokens
AU2002248552A1 (en) System and method for processing multi-currency transactions at a point of sale
GB0012839D0 (en) Processors having compressed instruction and method of compressing instructions for processors
NO20025416L (no) System og fremgangsmåte ved ekspanderbar komplettering
EP1297417A4 (en) DEVICE AND METHOD FOR PROVIDING THE GROUPING OF COMMANDS IN A VLIW PROCESSOR
GB0306433D0 (en) Methods and apparatus for implementing financial transactions
GB2359172B (en) Apparatus for controlling the rental and sale of age-controlled merchandise and for controlling access to age-controlled services
IL208346A0 (en) Process for removal of homopolymeric portion from analyte(s) and library of analyte(s)
DK1463683T3 (da) Fremgangsmåde og arrangement ved ladesøjle
AU2003253159A1 (en) Apparatus, method ,and compiler enabling processing of load immediate instructions in a very long instruction word processor
NO20021458D0 (no) Fremgangsmåte og apparat for måling av krefter ved tilstedev¶relse av ytre trykk
AU2001268233A1 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
AU7622400A (en) A method for precise trap handling in case of speculative and out-of-order loads
AU2001232270A1 (en) Transaction supporting facility and transaction supporting method
NO20020025D0 (no) Anordning for og fremgangsmåte ved utpröving av brukerprogrammer
NO20010703D0 (no) Fremgangsmåte og anordning ved fjerning av plattformdeler
NO20006537L (no) Fremgangsmåte og anordning ved bunndetektor
AU2002211191A8 (en) A method of sale auditing in private transaction of e-goods
GB2360860B (en) A method of and apparatus for facilitating on-line transactions
NO20023364D0 (no) Nytt peptid og screeningsfremgangsmåte ved bruk av dette peptid
AU2002319963A1 (en) Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
NO20002177D0 (no) FremgangsmÕte ved løftepumping og løftepumpe
PL340744A1 (en) Method of effecting payments and authorising transactions
NO20004812D0 (no) Middel og fremgangsmÕte ved pÕvisning og behandling av multippel sklerose (MS)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application